2015 Fiscal Year Final Research Report
Identification of compounds to suppress post-chemotherapeutic cancer relapse using drug-tolerant cancer subpopulations
| Project/Area Number |
25462034
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
Kume Kohei 岩手医科大学, 医歯薬総合研究所・神経科学研究部門, 助教 (10609663)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
Iwaya Takeshi 岩手医科大学, 医学部外科, 講師 (70405801)
|
|---|
| Project Period (FY) |
2013-04-01 – 2016-03-31
|
| Keywords | 化学療法 / 薬剤耐性 / RNAポリメラーゼ |
|---|
| Outline of Final Research Achievements |
Post-chemotherapeutic cancer relapse has been considered a result of population selection of drug-tolerant colonies (DTCs).The originally developed CoLA technology revealed that DTCs are of two distinct subpopulations expressing either stem cell- or epithelia-associated proteins. The TAF15 gene was identified as one of the uniquely expressed genes in DTCs. Subsequent TAF15 gene knockdown demonstrated a similar morphological change that was seen when RNA polymerase inhibitors were administered. An RNA polymerase inhibitor, alpha-amanitin (alpha-AMA) was identified for suppression of DTCs in vitro. Concurrent administration of alpha-AMA/CDDP suppressed peritoneal dissemination and prolonged survival in a mouse model.
|
| Free Research Field |
腫瘍外科、薬剤耐性、化学療法
|
